Background: Knowledge about the long-term stability of tablets outside the original container, e.g. as unit-doses, is limited. This leaves the pharmacist with the dilemma of seeking improved patient safety by use of unit-doses on one side, versus the lack of knowledge about the stability of the repackaged drug on the other. Aim: To screen the physical stability of moisture-sensitive repackaged tablets to identify those with the need for further chemical stability testing. Method: The physical stability of commercially available tablets (16 products) was investigated after 6 months of storage at ambient conditions in canisters for unit-dose production and after 3 months of storage as unit-doses in a climate chamber at 25°C/60% relative humidity (RH). Changes in appearance, colour and mass were investigated in addition to changes in disintegration time, friability and resistance to crushing. Results: The appearance and results of the physical tests for all products were acceptable and within the requirements of the European Pharmacopoeia, except for sodium valproate enteric-coated tablets (Orfiril). These tablets were significantly altered after 3 months of storage as unit-doses at 25°C/60% RH. However, when stored at ambient conditions the tablets complied with the tests. Conclusions: The current study was a screening study limited to the investigation of the physical stability of a selection of moisture-sensitive repackaged tablets. However, although the physical stability is acceptable, the chemical stability and dissolution rate may be altered. The physical tests outlined are simple but could be suitable for selecting candidates for further chemical stability testing.
INTRODUCTION
Repackaging of tablets into unit-doses is expected to improve patient safety since the tablet is fully identifiable until the moment of administration. However, such a practice increases the need for knowledge regarding the stability of tablets outside their original packaging. Although commercial service providers commonly practice repackaging of drugs, knowledge about long-term stability of oral drug products outside their original container is limited. Drug manufacturers have few, if any, requirements from authorities to provide such information 1 and there are few scientific publications covering this subject. The pharmacist is therefore often left with a dilemma, with lack of knowledge about the stability of the repackaged drug on one hand, versus the potential to obtain improved patient safety on the other. However, some authorities, such as the Swedish Medicinal Agency, provide information on product stability outside the original bulk packaging after dose dispensing. The information is based on documentation from the manufacturers. Also, a list based on information from manufacturers has been presented by Church et al. covering 392 products. 2 The Food and Drug Administration laboratories have performed some studies to provide further information regarding the effect of repackaging. [3] [4] [5] In one of these studies, furosemide tablets were chosen as a model drug due to its moisture sensitivity. In a review by Waterman, the stability of drugs by packaging with respect to moisture protection is described. 6 The relative humidity (RH) inside the packaging affects physical stability. This is in line with other studies finding that changes in physical stability are significant when tests are performed at the accelerated conditions outlined in the guidelines of the International Conference on Harmonization (ICH) (40°C/75% RH), while no change is seen when tests are performed at longterm conditions (25°C/60% RH). 4, 5, 7, 8 Another change seen in some products after repackaging is discolouration. [9] [10] [11] The authors are concerned by the effect a change in appearance may have on compliance. Possible formation of toxic photodegradants is another issue associated with discolouration. Glass et al. consider this to be critical when prochloroperazine tablets become grey. 10 Despite the confirmation of the physical and chemical stability within the British Pharmacopoeial limits, the discolouration and the potential for photodegradants to cause adverse effects in patients led the authors to conclude that the quality of the tablets had been compromised. A situation comparable to unit-dose repackaging is the use of dosage administration aids. An overview of stability studies performed on medicines in such aids can be found in a review paper by Tan and Kwan. 12 However, there is still a need for more investigations to assess the shelf lives of moisture-sensitive drugs after repackaging.
The aim of the current study was to focus on the physical stability after unit-dose repackaging of several tablets with known moisture sensitivity according to the Summary of Product Characteristics (SmPC). Although physical changes say nothing about changes in the amount of drug or drug release from the tablet, physical instability itself may make the product unusable. Since physical tests are easy to perform and make screening of a large amount of products possible, products may be excluded from unit-dose packaging early in the process without time-consuming chemical tests. Also, moderate changes in physical properties may indicate changes in drug content and dissolution rate, and may identify which products should be studied more carefully by chemical tests.
METHODS

Materials
The tablets included in this study were all obtained from commercial sources and are listed in Table 1 . The chemicals used for the disintegration testing were disodium hydrogen phosphate dihydrate, citric acid monohydrate and 12 mol/L hydrochloric acid (37%) from Merck GmbH (Darmstadt, Germany).
Repackaging of the Tablets
The repackaging of the tablets was performed in the hospital pharmacy production facility (Akershus University Hospital, Norway). The tablets were manually transferred, by using gloves, from the original containers into bulk storage canisters in class D facilities. For unit-dose production, canisters containing the tablets were transferred into a SwissLog PillPick system (SwissLog AG, Buchs, Switzerland) in which the unitdoses were produced. Each unit-dose consisted of a single tablet in a labelled, bar-coded, heat-sealed plastic bag. The packaging material (A000015 from SwissLog GmbH, Dortmund, Germany) complied with U.S. Pharmacopoeia Class C packaging material. 13 The bags were made from biaxially oriented polypropylene (BOPP) film co-extruded on both sides with polyolefinic copolymers. The thickness of the film was 40 lm. The canisters were stored for not more than 2 days at room temperature in the facility area at the hospital pharmacy prior to unitdose production.
Stability Study
Bulk samples of 300 tablets per canister (one canister for each drug product), unit-doses (approximately 100 bags of each drug product) and reference samples of each product (i.e. the drug product in the original container from the vendor) were included in the study. All samples were stored protected from light. The reference samples were investigated at time zero.
Storage at Ambient Conditions
Bulk tablets in canisters were stored at ambient temperature and humidity in the production facility at the hospital pharmacy and were investigated for physical stability after both 3 and 6 months. In addition, unitdoses of a modified-release formulation and a gastroresistant formulation of sodium valproate (Orfiril Retard and Orfiril 300 mg enterotablets) were included in the study and investigated after 3 months of storage in the SwissLog PillPick system to illustrate the stability under actual 'in process' conditions. The temperature in the production facility was aimed to be in the range 22-23°C and was continually monitored throughout the study by FMS Isoair Plus â (Malvern Instruments Ltd, Malvern, England), with the humidity level in the range of 35-45% RH.
Storage at Controlled Conditions (25°C/60% RH)
Unit-doses of all the preparations were stored in a climate chamber at 25°C/60% RH (Binder, KBF 720, Binder GmbH, Tuttlingen, Germany). These are the general conditions for long-term storage in a Mediterranean climatic zone in the ICH guidelines. 1 The samples were investigated for physical stability after 3 months.
Tablet Characterisation
After storage the tablets were visually inspected and tested for colour change in the L* a* b* colour space (CIELAB) using a Minolta spectrophotometer, Model CM-3500d (Minolta Co LTD, Osaka, Japan). The total CIELAB colour difference (DE Ã ab ) was determined as
where ΔL*, Δa* and Δb* indicate change in the brightness, red-green and yellow-blue directions, respectively, compared with the reference samples measured at timepoint zero. Three tablets from each batch were measured at each time point and the colour was measured at three different areas on each tablet. The samples were also tested for uniformity of mass (Ph.Eur.2.9.5) 14 . However, the disintegration test equipments (ERWEKA ZT 3-2 and ZT 220 Disintegration Testers, ERWEKA GmbH, Heusenstamm, Germany) were not suitable for some of the products due to the product's large size (Renvela) or its formulation characteristics (fast disintegrating tablets with embedded enteric coated pellets; Losec 10 and 20 mg, and Nexium 20 and 40 mg). The following method was applied for these products. Three tablets were placed in a 250 mL beaker containing distilled water (36-38°C). The beaker was swirled gently by hand, and the time when all tablets had disintegrated was manually recorded. 18 
Statistical Methods
Comparison of the results was performed by analysis of variance (ANOVA) followed by Tukey 0 s post hoc test.
The values after 3 and 6 months of storage were compared with the values at time-point zero. The level of significance used was p < 0.05 (Minitab 16 statistical 
RESULTS
The colour, average tablet weight and average resistance to crushing of all the products at the start of the study are listed in Table 1 . During the study the temperature in the production and storage facilities was room temperature typically in the range 21-23°C; never below 15°C and never above 25°C, monitored continuously by the FMS system.
Appearance and Colour Change
The visual appearance after storage in canisters for 6 months at ambient conditions was unchanged for all samples, and also for most tablets stored for 3 months as unit-doses under controlled conditions (25°C/60% RH). The only exceptions were unit-doses of the gastro-resistant formulations of sodium valproate (Orfiril 150 mg, 300 mg and 600 mg). These tablets had several holes and cracks in the coating (Figure 1 ). Also, their white colour became darker. This was confirmed spectrophotometrically with relatively large DE Ã ab values of these tablets (6.1, 9.0 and 6.4, respectively, for Orfiril 150 mg, 300 mg and 600 mg) as compared to the other tablets where all samples except Renvela, showed no visual colour change (data not shown). Renvela had DE Ã ab of 3.1 and a slightly yellow colour could be observed. It is worth noting that the appearance and the colour of the sodium valproate tablets stored as unit-doses at ambient conditions within the SwissLog PillPick system were unchanged with a DE Ã ab value of 1.1.
Physical Characteristics
Uniformity of Mass and Average Change in Mass
The changes in mass after storage for all the samples are shown in Figure 2 . The average change in mass was less than 5% for all samples stored at ambient conditions in canisters and for most of the tablets stored as unit-doses at 25°C/60% RH. The only exceptions were the gastro-resistant formulations of sodium valproate (Orfiril 150 mg, 300 mg and 600 mg) and the filmcoated tablets of sevelamer carbonate (Renvela) stored as unit-doses at 25°C/60% RH. These preparations had a weight increase in the range of 10-15%. However, Orfiril 150 mg was the only product which did not comply with the test uniformity of mass (Ph.Eur.2.9.5) 14 after the storage period.
Resistance to Crushing 75-90% of the initial value. On the other hand, the modified-release tablets of sodium valproate (Orfiril Retard) became harder after storage as unit-doses at these conditions. However, when stored as unit-doses for 3 months at ambient conditions in the PillPick system, no significant change was observed for either the Orfiril 300 mg enterotablets or the Orfiril Retard.
Friability and Disintegration
All products complied with Ph.Eur. friability requirements, 16 with a maximum loss of 0.4% (data not shown). All preparations also complied with the test for disintegration, 17 except for the gastro-resistant formulations of sodium valproate stored as unit-doses at 25°C/ 60% RH. As previously mentioned, these tablets lost their integrity during storage under these conditions, as seen in Figure 1 .
DISCUSSION
Repackaging of tablets into unit-dose containers improves patient safety by reducing errors in handling of the medicines. However, the quality of the tablets 
% change in resistance to crushing
Canister six months ambient conditions Unit dose three months 25 °C/60% RH * Figure 3 Change in resistance to crushing in percent of the reference sample for tablets stored as bulk in canisters in the production facility, or as unit-doses at 25°C/60% relative humidity (n = 10). *The values were outside the range of the instrument (>300 N). All individual tablets were within the range indicated by the error bars.
may be compromised when removed from the original packaging. The shelf life of the product given by the manufacturer is based on storage in the original container. However, in practice the tablets may be stored for months outside the original container when manufactured as unit-doses or dispensed in multicompartment compliance aids. During such storage it is likely that the shelf life can be affected both by variations in the environment and by the varying characteristics of the immediate repackaging material and container. Knowledge regarding tablet stability in such situations is limited, and more studies to document stability are required. 19 The current study was carried out to provide increased knowledge about the physical stability of repackaged tablets within the hospital pharmacy. Although all products included in this study were moisture-sensitive according to the SmPC, only the Orfiril gastro-resistant formulations were severely affected by the humid conditions when stored as unit-doses at 25°C/60% RH. However, when stored at ambient conditions in the production facility, both the colour and the mechanical strength were unchanged also for these tablets. This means that the humidity when storing these tablets is potentially critical and the product is perhaps not the best candidate for unit-dose production.
A change in visual appearance may influence patient compliance and make the product unacceptable for use, 9-11 regardless of changes or not in the drug content.
A combination of visual inspection and instrumental measurement was used for detecting colour change in this study. There are no formal acceptance criteria regarding the spectrophotometric colour change test, but a value of two for DE Ã ab has previously been suggested as a tolerance limit for visible changes for film-coated tablets of ofloxacin. 20 In the present study the highest value measured for tablets with no visible colour change was DE Ã ab = 3.38 (Losec MUPS 20 mg; pink tablets), while the lowest value visible by eye was DE Ã ab = 3.13 (Renvela; white tablets turning slightly yellow). Since visible colour change depends both on colour and the direction of colour change, 20 the discrepancies could be caused by different colours of the tablets. Another physical parameter which could make the tablets unsuitable for use is change in their mechanical strength. It is reasonable to assume that the mechanical strength could be affected by water absorption, which would also result in an increase in weight. A weight increase was indeed evident for a large number of the unit-doses stored for 3 months at 25°C/60% RH (Figure 2) . This may be explained by diffusion of water molecules through the plastic film of the unit-dose bag -a phenomenon confirmed by testing the weight increase of samples of dried silica in unit-dose bags stored in humid conditions. A significant decrease in resistance to crushing was found for the tablets increasing in mass. Including tablets with weight increase >1%, a correlation between weight increase (%) and reduction in resistance to crushing (%) was seen (r 2 = 0.967). However, although the resistance to crushing changed significantly, it was still deemed as acceptable for most of the products and the friability was low (<0.4%). The only exception was the gastro-resistant formulations containing sodium valproate (Orfiril 150 mg, 300 mg and 600 mg). These tablets had the highest weight increase and became very soft, which is also in accordance with studies in the literature on physical stability of sodium valproate tablets repackaged into dose administration aids. 7, 8 In the current study only one type of plastic material was used for the unit-dose production. Other materials may have different barrier properties. Also, only one type of canister was used in this study; other types of canisters may have different barrier properties. However, for all types of canisters the tablets are removed from the original container and are thereby exposed to the surrounding environment. It is reasonable to expect that the tablet properties will be influenced both by the internal environment in the canisters, but also by the barrier properties of the canister material, the climate, the season of the year and the filling level of the canister. To summarise, all products included in this study were moisture-sensitive according to their manufacturers. The results show that the physical changes during storage outside the original container were minor for most of the products included in the study, both when stored at the ambient conditions in the production facility and as unitdoses at higher humidity (25°C/60% RH). However, a limitation of the study was that no chemical investigations were conducted. When water is present, chemical stability and changes in the dissolution rate become questions of particular concern. The physical tests outlined in this paper are easy to perform and within reach of what can be performed in a hospital pharmacy. The tests may be used as a rational first step to exclude candidates for unitdose packaging if the appearance or the mechanical strength is severely affected. Also, the tests could be used for the selection of tablets of particular concern for further chemical stability testing. The physical stability of a dosage form and the chemical stability may not align, as demonstrated by Llewelyn et al. for sodium valproate tablets repackaged into dose administration aids. 7 However, a combination of large changes in mechanical strength and weight increase indicate the need for further investigation of changes in dissolution rate and chemical instability.
